Plus   Neg

Ardelyx: AMPLIFY Study Meets Primary, All Key Secondary Endpoints - Quick Facts

Ardelyx, Inc. (ARDX) said a phase 3 study showed a statistically significant reduction in serum phosphorus levels for patients treated with tenapanor and phosphate binders compared to phosphate binders alone. The AMPLIFY study was carried out in patients with chronic kidney disease on dialysis whose hyperphosphatemia was not previously controlled with binders alone.

Mike Raab, CEO of Ardelyx, said: "We look forward to reporting results from our second Phase 3 monotherapy study, PHREEDOM, in the fourth quarter of this year. With additional positive results from that trial, we will complete our New Drug Application for tenapanor, encompassing two indications: monotherapy and combination therapy for the treatment of hyperphosphatemia."

Shares of Ardelyx were up 13 percent in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Follow RTT